Mucopolysaccharidoses are a group of rare inherited diseases where the body cannot properly break down long chains of sugar molecules, leading to their buildup in cells throughout the body and causing progressive damage to organs, bones, and tissues that can significantly impact a person’s life.
Understanding Mucopolysaccharidosis
Mucopolysaccharidoses, commonly shortened to MPS, represent a collection of rare inherited metabolic diseases that affect how the body processes certain complex molecules. These conditions occur when the body either doesn’t produce enough of specific enzymes or produces enzymes that don’t work correctly. The role of these enzymes is to break down long chains of sugar molecules called glycosaminoglycans, also known as mucopolysaccharides, which are found throughout the body in cells, blood, and connective tissues.[1]
When these enzymes are missing or malfunctioning, glycosaminoglycans accumulate in harmful amounts within the body’s cells and tissues. This buildup happens gradually over time, causing permanent and progressive cellular damage. The affected cells are unable to function properly, which leads to a wide range of symptoms that typically worsen as a person ages. The accumulation particularly affects bones, cartilage, tendons, the transparent part of the eye called the cornea, skin, and connective tissue, as well as the fluid that lubricates joints.[2]
Mucopolysaccharidoses belong to a larger category of disorders known as lysosomal storage diseases. Lysosomes are small compartments within cells that act like recycling centers, breaking down and processing waste materials. In MPS, these cellular recycling centers become overwhelmed with unprocessed glycosaminoglycans, causing the cells to malfunction and eventually die or fail to work correctly.[1]
Epidemiology
Mucopolysaccharidoses are considered rare diseases, meaning they affect a relatively small portion of the population. MPS type I, which is the most common form, occurs worldwide but remains uncommon. The severe form of MPS I, often called Hurler syndrome, affects approximately 1 in every 100,000 newborns. The milder forms of MPS I, which progress more slowly, are even rarer, occurring in about 1 in 500,000 newborns.[4][5]
MPS type II, also known as Hunter syndrome, primarily affects males because it is inherited through the X chromosome. This form occurs in approximately 1 in 100,000 to 150,000 male births. Other types of mucopolysaccharidosis are even less common, with varying rates across different populations and geographic regions.[3]
The prevalence of different MPS types varies among continents and ethnic groups, suggesting that genetic background and regional factors play a role in who is affected. Some forms appear more frequently in certain populations than others. MPS occurs worldwide and affects both males and females equally, with the exception of MPS type II, which predominantly affects males. The age at which symptoms appear and the severity of the disease can vary widely even within the same type of MPS.[3]
Mucopolysaccharidosis type IV, also called Morquio syndrome, affects an estimated 1 in 200,000 to 300,000 people in the United States, with type A accounting for about 95% of these cases. These statistics highlight just how rare these conditions are, which often contributes to delays in diagnosis as many healthcare providers may never encounter a case during their careers.[17]
Causes
Mucopolysaccharidoses are genetic disorders, meaning they are caused by changes or mutations in a person’s genes. These genetic changes affect the body’s ability to produce functional enzymes needed to break down glycosaminoglycans. Each type of MPS is caused by a mutation in a different gene, which corresponds to a specific enzyme deficiency. For example, MPS type I is caused by mutations in the IDUA gene, which provides instructions for making an enzyme called alpha-L-iduronidase.[4][8]
When the gene responsible for producing a particular enzyme is mutated, the enzyme either isn’t produced at all or doesn’t function properly. Without adequate enzyme activity, the glycosaminoglycans that the enzyme normally breaks down begin to accumulate in cells throughout the body. This accumulation is the root cause of all the symptoms and complications associated with mucopolysaccharidosis.[6]
Most forms of MPS are inherited in what’s called an autosomal recessive pattern. This means that for a child to develop the condition, they must inherit two copies of the mutated gene—one from each parent. Parents who carry just one copy of the mutated gene typically don’t show symptoms themselves but are carriers. When both parents are carriers, each of their children has a 25% chance of inheriting both mutated copies and developing MPS, a 50% chance of being a carrier like the parents, and a 25% chance of inheriting two normal copies of the gene.[4][8]
Risk Factors
The primary risk factor for developing mucopolysaccharidosis is having a family history of the condition. If both parents are carriers of a gene mutation that causes MPS, their children are at increased risk. Families with a known history of MPS or other lysosomal storage diseases should consider genetic counseling when planning to have children. Genetic counselors can help assess the risk and explain testing options available to prospective parents.[4]
While MPS can occur in any family without a known history of the condition, certain ethnic or regional populations may have slightly higher carrier rates for specific types of MPS. This is due to what’s known as founder effects, where genetic mutations become more common in isolated or closely related populations over generations. However, because these conditions are so rare overall, the absolute risk remains low even in populations with higher carrier rates.[3]
Consanguinity, which means marriage or reproduction between close blood relatives, increases the risk of autosomal recessive conditions like most forms of MPS. When parents are closely related, there is a higher chance that both carry the same rare genetic mutation. However, it’s important to note that most children with MPS are born to parents with no known family history of the condition and who are not related to each other.[4]
Unlike many other diseases, MPS cannot be caused or prevented by lifestyle factors, environmental exposures, or behaviors. The genetic mutations responsible for these conditions occur randomly or are inherited from parents, and there is nothing parents can do before or during pregnancy to prevent them if they are carriers. Understanding this can help reduce feelings of guilt that parents sometimes experience after their child is diagnosed.[10]
Symptoms
The symptoms of mucopolysaccharidoses vary considerably depending on which specific type a person has, but many features are shared across different forms. One of the most characteristic aspects of MPS is that symptoms are typically not apparent at birth. Most babies with MPS appear completely normal initially and may develop normally during their first months or even years of life. However, as glycosaminoglycans continue to accumulate in cells and tissues, symptoms gradually emerge and worsen over time.[2][3]
Physical symptoms commonly include distinctive facial features that healthcare providers sometimes describe as coarse. These features may include a flat nasal bridge, thick lips, an enlarged tongue, and a broad nose. Many children with MPS develop short stature with a disproportionately short trunk compared to their limbs. The medical term for this type of short stature is dwarfism, though not all individuals with MPS will have significantly reduced height.[1]
Skeletal abnormalities are prominent features of mucopolysaccharidoses. These can include abnormal bone size and shape, a condition called dysplasia, along with other skeletal irregularities. Many individuals develop an abnormally curved spine, either sideways (scoliosis) or with a forward curve (kyphosis). Joint problems are extremely common, with many people experiencing stiffness that limits movement. Some develop what’s called claw hand, where the fingers cannot fully straighten.[1][2]
Internal organs can also be affected. The liver and spleen frequently become enlarged, a condition called hepatosplenomegaly. Hernias, where internal tissues push through weak spots in the abdominal wall, occur commonly in individuals with MPS. The skin may become thickened and less flexible over time.[1]
The eyes and ears are often affected by mucopolysaccharidosis. Clouding of the cornea, the clear front surface of the eye, can develop and may impair vision. Some forms of MPS can lead to glaucoma or degeneration of the retina at the back of the eye. Hearing loss is extremely common, affecting about 70% of people with MPS. This can be either conductive hearing loss, where fluid buildup prevents sound from reaching the inner ear, or sensorineural hearing loss, where the delicate hair cells in the inner ear are damaged, or a combination of both types.[2][7]
Respiratory problems are frequent and can be serious. Many individuals experience recurring respiratory infections and obstruction of the airways. Sleep apnea, where breathing temporarily stops during sleep, is common and can be dangerous. The accumulation of glycosaminoglycans in tissues around the airways can make breathing difficult and can complicate medical procedures that require anesthesia.[1]
Neurological complications affect many people with MPS. Damage to neurons, the cells that send and receive signals throughout the body, can occur. Many experience pain from compression of nerves or nerve roots in the spinal cord or peripheral nervous system. A condition called carpal tunnel syndrome, which restricts hand mobility and function, is common. Some forms of MPS can cause communicating hydrocephalus, where the normal reabsorption of cerebrospinal fluid is blocked, causing increased pressure inside the head.[2]
Cognitive and behavioral effects vary greatly depending on the type of MPS. Some individuals have normal intelligence throughout their lives, while others may experience developmental delays, cognitive impairments, or severe behavioral problems. In severe forms like MPS I (Hurler syndrome), progressive mental retardation often begins after age two. In contrast, milder forms typically spare intellectual function.[2][4]
Cardiovascular problems are serious concerns in mucopolysaccharidosis. Heart valve abnormalities are very common as glycosaminoglycans accumulate in the valve tissues, causing them to thicken and not work properly. This can lead to heart failure over time. The heart muscle itself may become enlarged and weakened. These heart problems can be life-threatening and are a major cause of complications and reduced lifespan in people with MPS.[1]
Prevention
Because mucopolysaccharidoses are inherited genetic conditions, there is currently no way to prevent them from occurring in children who inherit the responsible gene mutations from their parents. However, there are important steps that families can take to identify their risk and make informed decisions about family planning.[4]
Genetic counseling is strongly recommended for couples who have a family history of MPS or other lysosomal storage diseases. Genetic counselors are healthcare professionals specially trained to help people understand genetic risks, interpret test results, and make informed decisions. They can assess a couple’s risk of having a child with MPS based on family history and can arrange for carrier testing if appropriate.[4]
Carrier testing can identify whether a person carries a gene mutation that could cause MPS even if they don’t have symptoms themselves. If both partners in a couple are found to be carriers of mutations in the same gene, they face a 25% chance with each pregnancy of having a child affected by MPS. With this knowledge, couples can consider various options, including prenatal testing during pregnancy.[4]
Prenatal testing is available for families known to be at risk for MPS. Two main procedures can be used during pregnancy to test whether a developing baby has inherited the genetic mutations that cause MPS. Amniocentesis involves taking a sample of the fluid surrounding the baby, while chorionic villus sampling takes a small sample of placental tissue. Both procedures can be used to test for genetic mutations or measure enzyme levels. These tests allow parents to know before birth whether their child will have MPS, which can help with planning for the specialized care the child may need.[4]
In some regions, newborn screening programs have been expanded to include testing for certain types of MPS. Early detection through newborn screening, even before symptoms appear, can allow for earlier treatment initiation, which may improve outcomes. However, newborn screening for MPS is not yet universal and availability varies by location.[4]
Pathophysiology
The pathophysiology of mucopolysaccharidoses involves a cascade of events that begins at the molecular level and eventually leads to widespread organ and tissue damage. Understanding how these processes unfold helps explain why the symptoms of MPS are so varied and progressive in nature.[6]
In a healthy person, cells continuously produce glycosaminoglycans as part of normal growth and tissue maintenance. These long chains of sugar molecules play important structural and functional roles in the body. Once they have served their purpose, glycosaminoglycans need to be broken down and recycled. This breakdown occurs inside lysosomes, the cellular compartments responsible for waste processing. Eleven different enzymes work together in a specific sequence to break down different types of glycosaminoglycans into simpler molecules that the cell can either reuse or eliminate.[1][2]
In mucopolysaccharidosis, one of these eleven enzymes is either completely absent or present but not functioning properly due to genetic mutations. When even a single enzyme in this breakdown pathway is deficient, the entire process stalls. Glycosaminoglycans that would normally be broken down and cleared from the cell instead begin to accumulate inside the lysosomes. Over time, more and more of these molecules collect, causing the lysosomes to swell and eventually overwhelming the cell’s capacity to function normally.[3]
Different types of MPS involve deficiencies in different enzymes, and each enzyme is responsible for breaking down specific glycosaminoglycans. For instance, in MPS type I, the enzyme alpha-L-iduronidase is deficient, leading to accumulation of dermatan sulfate and heparan sulfate. In MPS type II, the enzyme iduronate-2-sulfatase is missing, also leading to accumulation of these same glycosaminoglycans. The specific glycosaminoglycans that accumulate influence which tissues and organs are most severely affected, though there is considerable overlap in symptoms across different types.[6]
As cells throughout the body become laden with stored glycosaminoglycans, they begin to malfunction in various ways. In connective tissues, the accumulation interferes with normal tissue architecture and flexibility, leading to the joint stiffness and skeletal abnormalities characteristic of MPS. In the cornea of the eye, glycosaminoglycan deposits cause clouding that can impair vision. In heart valves, the accumulation causes thickening and stiffening, preventing the valves from opening and closing properly.[2]
The accumulation of glycosaminoglycans in the brain and spinal cord leads to neurological complications. In some types of MPS, particularly MPS type III (Sanfilippo syndrome), the neurological effects are especially severe and progressive. The stored material can damage neurons directly and can also trigger inflammatory processes that contribute to further damage. Compression of nerve roots by accumulating material in the spine leads to pain and can cause paralysis if severe enough.[2][3]
The cellular damage in MPS is both progressive and irreversible. Once cells have accumulated significant amounts of glycosaminoglycans and sustained damage, they cannot fully recover even if the accumulation is later stopped. This is why early treatment is so important—it aims to prevent or minimize damage before it becomes too extensive. The progressive nature of the cellular damage explains why symptoms typically worsen over time and why starting treatment as early as possible offers the best chance of preserving function.[6]
The accumulation of glycosaminoglycans also occurs in circulating blood and in the spaces between cells throughout the body. This can be detected through laboratory testing and is used as one method of diagnosing MPS. Urine tests can measure elevated levels of glycosaminoglycans being excreted by the body, while blood tests can measure the activity levels of specific enzymes to identify which one is deficient.[3]